TrialHuman vaccines & immunotherapeutics2026

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).

Vinita Jagannath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.